Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The SRY-box 2 pseudogene is a non-protein-coding sequence homologous to the SOX2 gene, a key pluripotency and neural development transcription factor. As a pseudogene, ENSG00000237586 does not encode a functional SOX2 protein. However, pseudogenes can sometimes be transcribed into RNA, and their transcripts may contribute to the regulation of their parent gene or other molecular processes, particularly by acting as competing endogenous RNAs or through modulation of regulatory factors at the RNA level. Pseudogene expression, including SOX2 pseudogene expression, has gained interest as a biomarker in cancer and may reflect disease state or subtype, but the pseudogene itself is not a therapeutic target and does not have a direct clinical mechanism of action[2][4]. This target does not represent an active protein or classical druggable entity; it is primarily of interest for molecular biology or biomarker research.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SRY-box 2 pseudogene.